Misplaced Pages

Liver cancer
Other names	Hepatic cancer, primary hepatic malignancy, primary liver cancer
CT scan of a liver with cholangiocarcinoma
Specialty	Gastroenterology Hepatology Oncology
Symptoms	Lump or pain in the right side below the rib cage, swelling of the abdomen, yellowish skin, easy bruising, weight loss, weakness
Usual onset	55 to 65 years old
Causes	hepatitis B, hepatitis C, alcoholism, aflatoxin, non-alcoholic fatty liver disease, liver flukes
Diagnostic method	Blood tests, medical imaging, tissue biopsy
Prevention	Immunization against hepatitis B, treating those infected with hepatitis B or C, decreasing exposure to aflatoxin, decreasing high levels of alcohol consumption
Treatment	Surgery, targeted therapy, radiation therapy
Prognosis	Five-year survival rates ~18% (US); 40% (Japan)
Frequency	618,700 (point in time in 2015)
Deaths	782,000 (2018)

Liver cancer, also known as hepatic cancer, primary hepatic cancer, or primary hepatic malignancy, is cancer that starts in the liver. Liver cancer can be primary in which the cancer starts in the liver, or it can be liver metastasis, or secondary, in which the cancer spreads from elsewhere in the body to the liver. Liver metastasis is the more common of the two liver cancers. Instances of liver cancer are increasing globally.

Primary liver cancer is globally the sixth-most frequent cancer and the fourth-leading cause of death from cancer. In 2018, it occurred in 841,000 people and resulted in 782,000 deaths globally. Higher rates of liver cancer occur where hepatitis B and C are common, including Asia and sub-Saharan Africa. Males are more often affected with hepatocellular carcinoma (HCC) than females. Diagnosis is most frequent among those 55 to 65 years old.

The leading cause of liver cancer is cirrhosis due to hepatitis B, hepatitis C, or alcohol. Other causes include aflatoxin, non-alcoholic fatty liver disease and liver flukes. The most common types are HCC, which makes up 80% of cases and intrahepatic cholangiocarcinoma. The diagnosis may be supported by blood tests and medical imaging, with confirmation by tissue biopsy.

Given that there are many different causes of liver cancer, there are many approaches to liver cancer prevention. These efforts include immunization against hepatitis B, hepatitis B treatment, hepatitis C treatment, decreasing alcohol use, decreasing exposure to aflatoxin in agriculture, and management of obesity and diabetes. Screening is recommended in those with chronic liver disease. For example, it is recommended that people with chronic liver disease who are at risk for hepatocellular carcinoma be screened every 6 months using ultrasound imaging.

Because liver cancer is an umbrella term for many types of cancer, the signs and symptoms depend on what type of cancer is present. Symptoms can be vague and broad. Cholangiocarcinoma is associated with sweating, jaundice, abdominal pain, weight loss, and liver enlargement. Hepatocellular carcinoma is associated with abdominal mass, abdominal pain, vomiting, anemia, back pain, jaundice, itching, weight loss and fever.

Treatment options may include surgery, targeted therapy and radiation therapy. In certain cases, ablation therapy, embolization therapy or liver transplantation may be used.

Classification

Liver cancer can come from the liver parenchyma as well as other structures within the liver such as the bile duct, blood vessels and immune cells There are many sub-types of liver cancer, the most common of which are described below.

Hepatocellular carcinoma

The most frequent liver cancer, accounting for approximately 75% of all primary liver cancers, is hepatocellular carcinoma (HCC). HCC is a cancer formed by liver cells, known as hepatocytes, that become malignant. In terms of cancer deaths, worldwide HCC is considered the 3rd most common cause of cancer mortalities.

In terms of HCC diagnosis, it is recommended that people with risk factors (including known chronic liver disease, cirrhosis, etc.) should receive screening ultrasounds. If the ultrasound shows a focal area that is larger than 1 centimeter in size, patients should then get a triple-phase contrast-enhanced CT or MRI scan. HCC can then be diagnosed radiologically using the Liver Imaging Reporting and Data System (LI-RADS). There is also a variant type of HCC that consists of both HCC and cholangiocarcinoma.

Intrahepatic cholangiocarcinoma

Cancer of the bile duct (cholangiocarcinoma and cholangiocellular cystadenocarcinoma) account for approximately 6% of primary liver cancers. Intrahepatic cholangiocarcinoma (CCA) is an epithelial cancer of the intra-hepatic biliary tree branches. Intrahepatic CCA is the second leading cause of primary liver cancer. It is more common in men and usually is diagnosed in 60-70 year olds. Risk factors for development of intrahepatic CCA include opisthorchus viverrini infection, Clonorchis sinensis infection, sclerosing cholangitis, choledochal cysts, past procedures of the biliary tree, exposure to thorotrast and dioxins, and cirrhosis. This cancer is usually asymptomatic until the disease has progressed. Symptoms include abdominal pain, night sweats, weight loss, and fatigue. Liver markers that can be increased with intrahepatic CCA are carcinoembryonic antigen (CEA), CA19-9, and CA-125.

Angiosarcoma and hemangiosarcoma

These are rare and aggressive liver cancers, yet are the third most common primary liver cancer making up 0.1-2.0% of primary liver cancer. Angiosarcoma and hemangiosarcoma of the liver come from the blood vessel's endothelial layer. These tumors have poor outcomes because they grow rapidly and metastasise easily. They are also hard to diagnose but are typically suspected on CT or MRI scans that show focal lesions with differing amounts of signal intensity (these tumors have a lot of bleeding or hemorrhage and subsequent dying of tissue (necrosis)). Biopsy with histopathological evaluation yields the definitive diagnosis. While the cause is often never identified (75% are idiopathic), they are associated with exposures to substances such as vinyl chloride, arsenic, thorotrast (e.g. occupational exposure). Radiation is also a risk factor. In adults, these tumors are more common in males; however, in children they are more common in females.

Even with surgery, prognosis is poor with most individuals not living longer than six months after diagnosis. Only 3% of individuals live longer than two years.

Hepatoblastoma

Another type of cancer formed by liver cells is hepatoblastoma, which is specifically formed by immature liver cells. It is a rare malignant tumor that primarily develops in children, and accounts for approximately 1% of all cancers in children and 79% of all primary liver cancers under the age of 15. Most hepatoblastomas form in the right lobe.

Metastasis to liver

Many cancers found in the liver are not true liver cancers but are cancers from other sites in the body that have spread to the liver (known as metastases). Frequently, the site of origin is the gastrointestinal tract, since the liver is close to many of these metabolically active, blood-rich organs near to blood vessels and lymph nodes (such as pancreatic cancer, stomach cancer, colon cancer and carcinoid tumors mainly of the appendix), but also from breast cancer, ovarian cancer, lung cancer, renal cancer, prostate cancer.

Children

The Children's Oncology Group (COG) has developed a protocol to help diagnose and manage childhood liver tumors.

Causes

Viral infection

Viral infection with hepatitis C virus (HCV) or Hepatitis B virus (HBV) is the chief cause of liver cancer in the world today, accounting for 80% of HCC. Men with chronic HCV or HBV are more likely to develop HCC than women with chronic HCV or HBV; however, the reasons for this gender difference is unknown. HBV infection is also linked to cholangiocarcinoma. The role of viruses other than HCV or HBV in liver cancer is much less clear, even though there is some evidence that co-infection of HBV and hepatitis D virus may increase the risk for HCC.

HBV and HCV can lead to HCC, because these viral infections cause massive inflammation, fibrosis, and eventual cirrhosis occurs within the liver. In addition, many genetic and epigenetic changes are formed in liver cells during HCV and HBV infection, which is a major factor in the production of the liver tumors. The viruses induce malignant changes in cells by altering gene methylation, affecting gene expression, and promoting or repressing cellular signal transduction pathways. By doing this, the viruses can prevent cells from undergoing a programmed form of cell death (apoptosis) and promote viral replication and persistence.

HBV and HCV also induce malignant changes by causing DNA damage and genomic instability. This involves the generation of reactive oxygen species, expression of proteins that interfere with DNA repair enzymes, and HCV induced activation of a mutator enzyme.

Cirrhosis

In addition to virus-related cirrhosis described above, other causes of cirrhosis can lead to HCC. Alcohol intake correlates with risk of HCC, and the risk is far greater in individuals with an alcohol-induced cirrhotic liver. There are a few disorders that are known to cause cirrhosis and lead to cancer, including hereditary hemochromatosis and primary biliary cirrhosis.

Aflatoxin

Aflatoxin exposure can lead to the development of HCC. The aflatoxins are a group of chemicals produced by the fungi Aspergillus flavus (the name comes from A. flavus toxin) and A. parasiticus. Food contamination by the fungi leads to ingestion of the chemicals, which are very toxic to the liver. Common foodstuffs contaminated with the toxins are cereals, peanuts, and other vegetables. The amount (dose) and how long (duration) that a person is in contact with aflatoxin is associated with HCC. Contamination of food is common in Africa, South-East Asia, and China. The mechanism by which aflatoxins cause cancer is through mutations and epigenetic alterations. Aflatoxins induce a spectrum of mutations, including in the p53 tumor suppressor gene, which is a mutation seen in many types of cancers. Mutation in p53, presumably in conjunction with other aflatoxin-induced mutations and epigenetic alterations, is likely a common cause of aflatoxin-induced carcinogenesis.

Nonalcoholic steatohepatitis (NASH) and Nonalcoholic fatty liver (NAFL)

NASH and NAFL is beginning to be called a risk factor for liver cancer, particularly HCC. In recent years, there has been a noted increase in liver transplantations for HCC that was attributable to NASH. More research is needed in this area and NASH/NAFL.

Other risk factors in adults

• High grade dysplastic nodules are precancerous lesions of the liver. Within two years, there is a risk for cancer arising from these nodules of 30–40%.
• Obesity and metabolic syndrome have emerged as an important risk factor, as they can lead to steatohepatitis.
• Diabetes increases the risk for HCC.
• Smoking increases the risk for HCC compared to non-smokers and previous smokers.
• There is around 5-10% lifetime risk of cholangiocarcinoma in people with primary sclerosing cholangitis.
• Liver fluke infection increases the risk for cholangiocarcinoma, and this is the reason why Thailand has particularly high rates of this cancer.
• Choledochal cysts, Caroli's disease, and congenital hepatic fibrosis are associated with cholangiocarcinoma development.
• Genetic conditions: untreated hereditary hemochromatosis, alpha-1-antitrypsin deficiency, glycogen storage diseases, porphyria cutanea tarda, Wilson's disease, tyrosinemia have all been associated with development of HCC.
• Oral contraceptive pill: There is insufficient evidence to label oral contraceptives as a risk factor. However, recent studies have found that taking oral contraceptives for longer than five years is associated with HCC.

Children

Childhood liver cancer is uncommon. The liver cancer sub-types most commonly seen in children are hepatoblastoma, hepatocellular carcinoma, embryomal sarcoma of liver, infantile choriocarcinoma of liver, and biliary rhabdomyosarcoma. Increased risk for liver cancer in children can be caused by Beckwith–Wiedemann syndrome (associated with hepatoblastoma), familial adenomatous polyposis (associated with hepatoblastoma), low birth weight (associated with hepatoblastoma), Progressive familial intrahepatic cholestasis (associated with HCC) and Trisomy 18 (associated with hepatoblastoma).

Diagnosis

Many imaging modalities are used to aid in the diagnosis of liver cancer. For HCC these include medical ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI). When imaging the liver with ultrasound, large lesions are likely to be HCC (e.g., a mass greater than 2 cm has more than 95% chance of being HCC).Given the blood flow to the liver, HCC would be most visible when the contrast flows through the arteries of the liver (also called the arterial phase) rather than when the contrast flows through the veins (also called the venous phase). Sometimes doctors will get a liver biopsy, if they are worried about HCC and the imaging studies (CT or MRI) do not have clear results. The majority of cholangiocarcimas occur in the hilar region of the liver, and often present as bile duct obstruction. If the cause of obstruction is suspected to be malignant, endoscopic retrograde cholangiopancreatography (ERCP), ultrasound, CT, MRI and magnetic resonance cholangiopancreatography (MRCP) are used.

Tumor markers, chemicals sometimes found in the blood of people with cancer, can be helpful in diagnosing and monitoring the course of liver cancers. High levels of alpha-fetoprotein (AFP) in the blood can be found in many cases of HCC and intrahepatic cholangiocarcinoma. Of note, AFP is most useful for monitoring if liver cancers come back after treatment rather than for initial diagnosis. Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 (CA 19–9), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). These tumor markers are found in primary liver cancers, as well as in other cancers and certain other disorders.

Prevention

Prevention of cancers can be separated into primary, secondary, and tertiary prevention. Primary prevention preemptively reduces exposure to a risk factor for liver cancer. One of the most successful primary liver cancer preventions is vaccination against hepatitis B. Vaccination against the hepatitis C virus is currently unavailable. Other forms of primary prevention are aimed at limiting transmission of these viruses by promoting safe injection practices, screening blood donation products, and screening high-risk asymptomatic individuals. Aflatoxin exposure can be avoided by post-harvest intervention to discourage mold, which has been effective in west Africa. Reducing alcohol use disorder, obesity, and diabetes mellitus would also reduce rates of liver cancer. Diet control in hemochromatosis could decrease the risk of iron overload, decreasing the risk of cancer.

Secondary prevention includes both cure of the agent involved in the formation of cancer (carcinogenesis) and the prevention of carcinogenesis if this is not possible. Cure of virus-infected individuals is not possible, but treatment with antiviral drugs can decrease the risk of liver cancer. Chlorophyllin may have potential in reducing the effects of aflatoxin.

Tertiary prevention includes treatments to prevent the recurrence of liver cancer. These include the use of surgical interventions, chemotherapy drugs, and antiviral drugs.

Treatment

General considerations

Like many cancers, treatment depends on the specific type of liver cancer as well as stage of the cancer. The main way cancer is staged is based on the TMN staging systems. There are also liver cancer specific staging systems, each of which has treatment options that may result in a non recurrence of cancer, or cure. For example, for HCC it is common to use the Barcelona Clinic Liver Cancer Staging System.

Treatments include surgery, medications, and ablation methods. There are many chemotherapeutic drugs approved for liver cancer including: atezolizumab, nivolumab, pembrolizumab, regorafenib. Increasingly, immunotherapy agents (also called targeted cancer therapies or precision medicine) are being used to treat hepatobiliary cancers.

Recent advances in liver cancer treatment are exploring T cells engineered with chimeric antigen receptors (CARs) targeting glypican-3 (GPC3), such as GAP T cells, showing potential in addressing GPC3-positive tumors, especially in pediatric liver cancers.

Hepatocellular carcinoma

This section's factual accuracy may be compromised due to out-of-date information. Please help update this article to reflect recent events or newly available information. (June 2017)

Partial surgical resection is the recommended treatment for hepatocellular carcinoma (HCC) when patients have sufficient hepatic function reserve. 5-year survival rates after resection have massively improved over the last few decades and can now range from 41 to 74%. However, recurrence rates after resection can exceed 70%, whether due to spread of the initial tumor or formation of new tumors . Liver transplantation can also be considered in cases of HCC where this form of treatment can be tolerated and the tumor fits specific criteria (such as the Milan criteria). In general, patients who are being considered for liver transplantation have multiple hepatic lesions, severe underlying liver dysfunction, or both.

Percutaneous ablation is the only non-surgical treatment that can offer cure. There are many forms of percutaneous ablation, which consist of either injecting chemicals into the liver (ethanol or acetic acid) or producing extremes of temperature using radio frequency ablation, microwaves, lasers or cryotherapy. Of these, radio frequency ablation has one of the best reputations in HCC, but the limitations include inability to treat tumors close to other organs and blood vessels due to heat generation and the heat sink effect, respectively. In addition, long-term of outcomes of percutaneous ablation procedures for HCC have not been well studied. In general, surgery is the preferred treatment modality when possible.

Systemic chemotherapeutics are not routinely used in HCC, although local chemotherapy may be used in a procedure known as transarterial chemoembolization (TACE). In this procedure, drugs that kill cancer cells and interrupt the blood supply are applied to the tumor. Because most systemic drugs have no efficacy in the treatment of HCC, research into the molecular pathways involved in the production of liver cancer produced sorafenib, a targeted therapy drug that prevents cell proliferation and blood cell growth. Sorafenib obtained FDA approval for the treatment of advanced hepatocellular carcinoma in November 2007. This drug provides a survival benefit for advanced HCC.

Transarterial radioembolization (TRACE) is another option for HCC. In this procedure, radiation treatment is targeted at the tumor. TRACE is still considered an add on treatment rather than the first choice for treatment of HCC, as dual treatments of radiotherapy plus chemoembolization, local chemotherapy, systemic chemotherapy or targeted therapy drugs may show benefit over radiotherapy alone.

Ablation methods (e.g. radiofrequency ablation or microwave ablation) are also an option for HCC treatment. This method is recommended for small, localized liver tumors as it is recommended that the area treated with radiofrequency ablation should be 2 centimeters or less.

Intrahepatic cholangiocarcinoma

Resection is an option in cholangiocarcinoma, but fewer than 30% of cases of cholangiocarcinoma are resectable at diagnosis. The reason the majority of intrahepatic cholangiocarcinomas are not able to be surgically removed is because there are often multiple focal tumors within the liver. After surgery, recurrence rates are up to 60%. Liver transplant may be used where partial resection is not an option, and adjuvant chemoradiation may benefit some cases.

60% of cholangiocarcinomas form in the perihilar region and photodynamic therapy can be used to improve quality of life and survival time in these un-resectable cases. Photodynamic therapy is a novel treatment that uses light activated molecules to treat the tumor. The compounds are activated in the tumor region by laser light, which causes the release of toxic reactive oxygen species, killing tumor cells.

Systemic chemotherapies such as gemcitabine and cisplatin are sometimes used in inoperable cases of cholangiocarcinoma.

Radio frequency ablation, transarterial chemoembolization and internal radiotherapy (brachytherapy) all show promise in the treatment of cholangiocarcinoma and can sometimes improve bile flow, which can decrease the symptoms a patient experiences.

Radiotherapy may be used in the adjuvant setting or for palliative treatment of cholangiocarcinoma.

Hepatoblastoma

Removing the tumor by either surgical resection or liver transplant can be used in the treatment of hepatoblastoma. In some cases surgery can offer a cure. Chemotherapy may be used before and after surgery and transplant.

Chemotherapy, including cisplatin, vincristine, cyclophosphamide, and doxorubicin are used for the systemic treatment of hepatoblastoma. Out of these drugs, cisplatin seems to be the most effective.

Angiosarcoma and hemangiosarcoma

Many of these tumors end up not being amenable to surgical treatment. Treatment options include surgically removing parts of the liver that are affected. Liver transplantation and chemotherapy are not effective for angiosarcomas and hemangiosarcomas of the liver.

Epidemiology

Globally, liver cancer is common and increasing. Most recent epidemiological data suggests that liver cancer is in the Top 10 for both prevalence and mortality (noted to be the sixth-leading cause of cancer and fourth most-common cause of death). The Global Burden of Disease Liver Cancer Collaboration found that from 1990 to 2015 the new cases of liver cancer per year increased by 75%. Estimates based on most recent data suggest that each year there are 841,000 new liver cancer diagnoses and 782,000 deaths across the globe. Liver cancer is the most common cancer in Egypt, the Gambia, Guinea, Mongolia, Cambodia, and Vietnam. In terms of gender breakdown, globally liver cancer is more common in men than in women.

Given that HCC is the most-common type of liver cancer, the areas around the world with the most new cases of HCC each year are Northern and Western Africa as well as Eastern and South-Eastern Asia. China has 50% of HCC cases globally, and more than 80% of total cases occur in sub-Saharan Africa or in East-Asia due to hepatitis B virus. In these high disease burden areas, evidence indicates the majority of the HBC and HCV infections occur via perinatal transmission (also called mother-to-child transmission). However, it is important to note that the risk factors for HCC varies by geographic region. For example, in China, chronic HBV infection and aflatoxin are the largest risk factors; whereas, in Mongolia, it is a combination of HBV and HCV co-infection and high levels of alcohol use that are driving the high levels of HCC.

In terms of intrahepatic cholangiocarcinoma, we currently do not have sufficient epidemiological data because it is a rare cancer. According to the United States National Cancer Institute, the incidence of cholangiocarcinoma is not known. Cholangiocarcinoma also has a significant geographical distribution, with Thailand showing the highest rates worldwide due to the presence of liver fluke.

In the United States, there were 42,810 new cases of liver and intrahepatic bile duct cancer in 2020, which represents 2.4% of all new cancer cases in the United States. There are about 89.950 people who have liver and intrahepatic liver cancer in the United States. In terms of mortality, the 5-year survival rate for liver and intrahepatic bile duct cancers in the United States is 19.6%. In the United States, there is an estimated 1% chance of getting liver cancer across the lifespan, which makes this cancer relatively rare. Despite the low number of cases, it is one of the top causes of cancer deaths.

References

1. ^ "Adult Primary Liver Cancer Treatment (PDQ®)–Patient Version". NCI. 6 July 2016. Archived from the original on 2 October 2016. Retrieved 29 September 2016.
2. ^ "SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer". NCI. Archived from the original on 2017-07-28.
3. ^ World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.6. ISBN 978-9283204299.
4. ^ Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. (GBD 2013 Mortality Causes of Death Collaborators) (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–171. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
5. "がん診療連携拠点病院等院内がん登録生存率集計：[国立がん研究センター がん登録・統計]". ganjoho.jp. Retrieved 2 February 2020.
6. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
7. ^ Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA. 68 (6): 394–424. doi:10.3322/caac.21492. PMID 30207593. S2CID 52188256.
8. ^ Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V (April 2015). "Liver cancer: Approaching a personalized care". Journal of Hepatology. 62 (1 Suppl): S144–S156. doi:10.1016/j.jhep.2015.02.007. PMC 4520430. PMID 25920083.
9. ^ Mantovani A, Targher G (July 2017). "Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease". Annals of Translational Medicine. 5 (13): 270. doi:10.21037/atm.2017.04.41. PMC 5515814. PMID 28758096.
10. ^ Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. (December 2017). "The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015". JAMA Oncology. 3 (12): 1683–1691. doi:10.1001/jamaoncol.2017.3055. hdl:10037/11672. PMC 5824275. PMID 28983565.
11. Cholangiocarcinoma at eMedicine
12. "Liver tumors in Children". Boston Children's Hospital. Archived from the original on 2011-06-04.
13. "Liver cancer - Symptoms and causes". Mayo Clinic. Retrieved 2023-02-06.
14. Table 37.2 in: Sternberg S (2012). Sternberg's diagnostic surgical pathology. Place of publication not identified: LWW. ISBN 978-1-4511-5289-0. OCLC 953861627.
15. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (October 2019). "A global view of hepatocellular carcinoma: trends, risk, prevention and management". Nature Reviews. Gastroenterology & Hepatology. 16 (10): 589–604. doi:10.1038/s41575-019-0186-y. PMC 6813818. PMID 31439937.
16. Mokdad AA, Singal AG, Yopp AC (2015-12-22). "JAMA PATIENT PAGE. Liver Cancer". JAMA. 314 (24): 2701. doi:10.1001/jama.2015.15425. PMID 26720038.
17. ^ "Adult Primary Liver Cancer Treatment (PDQ®)–Health Professional Version - National Cancer Institute". www.cancer.gov. 2021-01-15. Retrieved 2021-02-25.
18. Mitchell DG, Bruix J, Sherman M, Sirlin CB (March 2015). "LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions". Hepatology. 61 (3): 1056–1065. doi:10.1002/hep.27304. PMID 25041904. S2CID 205894014.
19. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. (December 2012). "Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update". Gut. 61 (12): 1657–1669. doi:10.1136/gutjnl-2011-301748. PMID 22895392.
20. ^ Ahmed I, Lobo DN (January 2009). "Malignant tumours of the liver". Surgery. 27 (1). Oxford: 30–37. doi:10.1016/j.mpsur.2008.12.005.
21. ^ Dooley JS, Lok AS, Garcia-Tsao G, Pinzani M (8 June 2018). Sherlock's Diseases of the Liver and Biliary System. John Wiley & Sons. pp. 705–729. ISBN 978-1-119-23764-8. OCLC 1187411089.
22. ^ Kumar A, Sharma B, Samant H (2021). "Liver Angiosarcoma". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30855812. Retrieved 2021-02-25.
23. ^ Chen N, Yu A, Jung J (2018-05-31). "Editor's Pick: Primary Hepatic Angiosarcoma: A Brief Review of the Literature". Emj Hepatol Hepatology 6.1 2018. 6 (1): 64–71. doi:10.33590/emjhepatol/10314175. S2CID 53063864. Retrieved 2021-02-25.
24. PDQ Pediatric Treatment Editorial Board (2002), "Childhood Liver Cancer Treatment (PDQ®): Health Professional Version", PDQ Cancer Information Summaries, Bethesda (MD): National Cancer Institute (US), PMID 26389232, retrieved 2021-02-25
25. Khanna R, Verma SK (September 2018). "Pediatric hepatocellular carcinoma". World Journal of Gastroenterology. 24 (35): 3980–3999. doi:10.3748/wjg.v24.i35.3980. PMC 6148423. PMID 30254403.
26. ^ Emre S, McKenna GJ (December 2004). "Liver tumors in children". Pediatric Transplantation. 8 (6): 632–638. doi:10.1111/j.1399-3046.2004.00268.x. PMID 15598339. S2CID 35883310.
27. ^ "Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version - National Cancer Institute". www.cancer.gov. 2020-11-27. Retrieved 2021-02-25.
28. ^ Arzumanyan A, Reis HM, Feitelson MA (February 2013). "Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma". Nature Reviews. Cancer. 13 (2): 123–135. doi:10.1038/nrc3449. PMID 23344543. S2CID 29447705.
29. Rosen HR (June 2011). "Clinical practice. Chronic hepatitis C infection". The New England Journal of Medicine. 364 (25): 2429–2438. doi:10.1056/NEJMcp1006613. PMID 21696309. S2CID 19755395.
30. ^ "General Information About Adult Primary Liver Cancer". National Cancer Instituteb. 1980-01-01. Archived from the original on 2 January 2013. Retrieved 13 January 2013.
31. Ralphs S, Khan SA (May 2013). "The role of the hepatitis viruses in cholangiocarcinoma". Journal of Viral Hepatitis. 20 (5): 297–305. doi:10.1111/jvh.12093. PMID 23565610. S2CID 44318080.
32. Kew MC (March 2013). "Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update". Journal of Viral Hepatitis. 20 (3): 149–157. doi:10.1111/jvh.12043. PMID 23383653. S2CID 206164005.
33. Dooley JS, Lok AS, Garcia-Tsao G, Pinzani M (8 June 2018). Dooley JS, Lok AS, Garcia-Tsao G, Pinzani M (eds.). Sherlock's diseases of the liver and biliary system. John Wiley & Sons. ISBN 978-1-119-23756-3. OCLC 1019837000.
34. Jeong SW, Jang JY, Chung RT (December 2012). "Hepatitis C virus and hepatocarcinogenesis". Clinical and Molecular Hepatology. 18 (4): 347–356. doi:10.3350/cmh.2012.18.4.347. PMC 3540370. PMID 23323249.
35. Takeda H, Takai A, Inuzuka T, Marusawa H (January 2017). "Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis". Journal of Gastroenterology. 52 (1): 26–38. doi:10.1007/s00535-016-1273-2. PMID 27714455.
36. Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT (2014). "Involvement of DNA damage response pathways in hepatocellular carcinoma". BioMed Research International. 2014: 153867. doi:10.1155/2014/153867. PMC 4022277. PMID 24877058.
37. Du X, Hidayat K, Shi BM (June 2017). "Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies". Bioscience Reports. 37 (3): BSR20160474. doi:10.1042/BSR20160474. PMC 5426287. PMID 28336766.
38. Fattovich G, Stroffolini T, Zagni I, Donato F (November 2004). "Hepatocellular carcinoma in cirrhosis: incidence and risk factors". Gastroenterology. 127 (5 Suppl 1): S35–S50. doi:10.1053/j.gastro.2004.09.014. PMID 15508101.
39. ^ Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. (October 2016). "Hepatocellular carcinoma: a review". Journal of Hepatocellular Carcinoma. 3: 41–53. doi:10.2147/JHC.S61146. PMC 5063561. PMID 27785449.
40. ^ Smela ME, Currier SS, Bailey EA, Essigmann JM (April 2001). "The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis". Carcinogenesis. 22 (4): 535–545. doi:10.1093/carcin/22.4.535. PMID 11285186.
41. Perduca V, Omichessan H, Baglietto L, Severi G (January 2018). "Mutational and epigenetic signatures in cancer tissue linked to environmental exposures and lifestyle". Current Opinion in Oncology. 30 (1): 61–67. doi:10.1097/CCO.0000000000000418. PMID 29076965. S2CID 20842446.
42. Dai Y, Huang K, Zhang B, Zhu L, Xu W (November 2017). "Aflatoxin B1-induced epigenetic alterations: An overview". Food and Chemical Toxicology. 109 (Pt 1): 683–689. doi:10.1016/j.fct.2017.06.034. PMID 28645871.
43. ^ "Liver (Hepatocellular) Cancer Prevention (PDQ®)–Health Professional Version - National Cancer Institute". www.cancer.gov. 2005-05-23. Retrieved 2021-02-23.
44. Di Tommaso L, Sangiovanni A, Borzio M, Park YN, Farinati F, Roncalli M (April 2013). "Advanced precancerous lesions in the liver". Best Practice & Research. Clinical Gastroenterology. 27 (2): 269–284. doi:10.1016/j.bpg.2013.03.015. PMID 23809245.
45. ^ Chuang SC, La Vecchia C, Boffetta P (December 2009). "Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection". Cancer Letters. 286 (1): 9–14. doi:10.1016/j.canlet.2008.10.040. hdl:11585/682618. PMID 19091458.
46. ^ Razumilava N, Gores GJ (January 2013). "Classification, diagnosis, and management of cholangiocarcinoma". Clinical Gastroenterology and Hepatology. 11 (1): 13–21.e1, quiz e3–4. doi:10.1016/j.cgh.2012.09.009. PMC 3596004. PMID 22982100.
47. ^ Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (Mar–Apr 2011). "Global cancer statistics". CA. 61 (2): 69–90. doi:10.3322/caac.20107. PMID 21296855. S2CID 30500384.
48. ^ Patel T (April 2011). "Cholangiocarcinoma--controversies and challenges". Nature Reviews. Gastroenterology & Hepatology. 8 (4): 189–200. doi:10.1038/nrgastro.2011.20. PMC 3888819. PMID 21460876.
49. DeBaun MR, Tucker MA (March 1998). "Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry". The Journal of Pediatrics. 132 (3 Pt 1): 398–400. doi:10.1016/S0022-3476(98)70008-3. PMID 9544889.
50. ^ Spector LG, Birch J (November 2012). "The epidemiology of hepatoblastoma". Pediatric Blood & Cancer. 59 (5): 776–779. doi:10.1002/pbc.24215. PMID 22692949. S2CID 65545.
51. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E (January 2009). "Progressive familial intrahepatic cholestasis". Orphanet Journal of Rare Diseases. 4: 1. doi:10.1186/1750-1172-4-1. PMC 2647530. PMID 19133130.
52. Ariff B, Lloyd CR, Khan S, Shariff M, Thillainayagam AV, Bansi DS, et al. (March 2009). "Imaging of liver cancer". World Journal of Gastroenterology. 15 (11): 1289–1300. doi:10.3748/wjg.15.1289. PMC 2658841. PMID 19294758.
53. Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M (2013). "Serum markers of intrahepatic cholangiocarcinoma". Disease Markers. 34 (4): 219–228. doi:10.1155/2013/196412. PMC 3809974. PMID 23396291.
54. Zhao YJ, Ju Q, Li GC (July 2013). "Tumor markers for hepatocellular carcinoma". Molecular and Clinical Oncology. 1 (4): 593–598. doi:10.3892/mco.2013.119. PMC 3915636. PMID 24649215.
55. ^ Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA. 68 (6): 394–424. doi:10.3322/caac.21492. PMID 30207593.
56. ^ Hoshida Y, Fuchs BC, Tanabe KK (November 2012). "Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges". Current Cancer Drug Targets. 12 (9): 1129–1159. doi:10.2174/156800912803987977. PMC 3776581. PMID 22873223.
57. Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, et al. (2020-03-12). "Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West". PLOS ONE. 15 (3): e0230005. Bibcode:2020PLoSO..1530005Y. doi:10.1371/journal.pone.0230005. PMC 7067409. PMID 32163475.
58. Bruix J, Sherman M (March 2011). "Management of hepatocellular carcinoma: an update". Hepatology. 53 (3): 1020–1022. doi:10.1002/hep.24199. PMC 3084991. PMID 21374666.
59. Chen CH (2016-12-01). "Percutaneous radiofrequency ablation for hepatocellular carcinoma: Shortened duration does not comprise its efficacy". Advances in Digestive Medicine. 3 (4): 149–150. doi:10.1016/j.aidm.2016.10.001. S2CID 44047011.
60. "Drugs Approved for Liver Cancer - National Cancer Institute". www.cancer.gov. 2011-10-04. Retrieved 2021-02-25.
61. "Targeted Cancer Therapies Fact Sheet - National Cancer Institute". www.cancer.gov. 2021-01-25. Retrieved 2021-02-25.
62. Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, et al. (May 2017). "Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity". Human Gene Therapy. 28 (5): 437–448. doi:10.1089/hum.2016.025. PMC 5444493. PMID 27530312.
63. Clinical trial number NCT02932956 for "Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)" at ClinicalTrials.gov
64. Bruix J, Sherman M (March 2011). "Management of hepatocellular carcinoma: an update". Hepatology. 53 (3): 1020–1022. doi:10.1002/hep.24199. PMC 3084991. PMID 21374666.
65. Wang Z, Zhang G, Wu J, Jia M (August 2013). "Adjuvant therapy for hepatocellular carcinoma: current situation and prospect". Drug Discoveries & Therapeutics. 7 (4): 137–143. doi:10.5582/ddt.2013.v7.4.137. PMID 24071575.
66. ^ de Lope CR, Tremosini S, Forner A, Reig M, Bruix J (2012). "Management of HCC". Journal of Hepatology. 56 (Suppl 1): S75–S87. doi:10.1016/S0168-8278(12)60009-9. PMID 22300468. S2CID 5349344.
67. Keating GM, Santoro A (2009). "Sorafenib: a review of its use in advanced hepatocellular carcinoma". Drugs. 69 (2): 223–240. doi:10.2165/00003495-200969020-00006. PMID 19228077.
68. Feng M, Ben-Josef E (October 2011). "Radiation therapy for hepatocellular carcinoma". Seminars in Radiation Oncology. 21 (4): 271–277. doi:10.1016/j.semradonc.2011.05.002. PMID 21939856.
69. ^ Tarasik A, Jaroszewicz J, Januszkiewicz M (March 2017). "Surgical treatment of liver tumors - own experience and literature review". Clinical and Experimental Hepatology. 3 (1): 1–8. doi:10.5114/ceh.2017.65498. PMC 5497454. PMID 28856283.
70. ^ "Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version - National Cancer Institute". www.cancer.gov. 2021-02-19. Retrieved 2021-02-25.
71. ^ Ulstrup T, Pedersen FM (February 2013). "". Ugeskrift for Laeger. 175 (9): 579–582. PMID 23608009.
72. ^ Kuhlmann JB, Blum HE (May 2013). "Locoregional therapy for cholangiocarcinoma". Current Opinion in Gastroenterology. 29 (3): 324–328. doi:10.1097/MOG.0b013e32835d9dea. PMID 23337933. S2CID 37403999.
73. Ortner MA (September 2011). "Photodynamic therapy for cholangiocarcinoma". Lasers in Surgery and Medicine. 43 (7): 776–780. doi:10.1002/lsm.21106. PMID 22057505. S2CID 36852386.
74. Valero V, Cosgrove D, Herman JM, Pawlik TM (August 2012). "Management of perihilar cholangiocarcinoma in the era of multimodal therapy". Expert Review of Gastroenterology & Hepatology. 6 (4): 481–495. doi:10.1586/egh.12.20. PMC 3538366. PMID 22928900.
75. Meyers RL, Czauderna P, Otte JB (November 2012). "Surgical treatment of hepatoblastoma". Pediatric Blood & Cancer. 59 (5): 800–808. doi:10.1002/pbc.24220. PMID 22887704. S2CID 27329163.
76. Perilongo G, Malogolowkin M, Feusner J (November 2012). "Hepatoblastoma clinical research: lessons learned and future challenges". Pediatric Blood & Cancer. 59 (5): 818–821. doi:10.1002/pbc.24217. PMID 22678761. S2CID 19059413.
77. El-Serag HB, Rudolph KL (June 2007). "Hepatocellular carcinoma: epidemiology and molecular carcinogenesis". Gastroenterology. 132 (7): 2557–2576. doi:10.1053/j.gastro.2007.04.061. PMID 17570226.
78. Khan SA, Toledano MB, Taylor-Robinson SD (2008). "Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma". HPB. 10 (2): 77–82. doi:10.1080/13651820801992641. PMC 2504381. PMID 18773060.
79. ^ "Cancer of the Liver and Intrahepatic Bile Duct - Cancer Stat Facts". SEER. Retrieved 2021-02-23.

External links

• EASL Guideline
• Liver cancer information from Cancer Research UK

• Digestive system neoplasia
• Diseases of liver
• Hepatology